T2DNCT04011904
The Role of Traditional or Western Diet in the TBC1D4 Gene on Glucose Homeostasis in Greenland Inuits
A study testing Cross-over study in people with T2D, run by University of Copenhagen at 1 site in Denmark.
Trial summary
Studies of Greenland Inuit before the 1980s found a low prevalence of type 2 diabetes (T2D) compared to Western populations. However, recent population studies in Greenland found a notably high prevalence of diabetes (9%) and pre-diabetes (19%) in the adult population. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- T2D
- What is being tested?
- Cross-over study
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- 1 siteDenmark
- Study dates
- 15 Apr 2019to 23 Nov 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants who have provided written informed consent
- Age between 18 and 80 years
- Homozygous carriers of the nonsense p.Arg684Ter variant in the TBC1D4 gene (cases)
- Homozygous non-carriers of the nonsense p.Arg684Ter variant in the TBC1D4 gene (control)
Who cannot join
- If study participants do not want to know whether they are carriers or non-carriers of the p.Arg684Ter variant in the TBC1D4 gene they will not be able to participate in the study
- BMI ≥ 18.5 kg/m2
- Diagnosis of diabetes (HbA1c ≥ 6,5% (48 mmol/mol)) or pharmacological treatment of diabetes (10).
- Use of peroral glucocorticoids
- Lack of compliance with the procedures in the study protocol, judged by Investigator
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Department of Exercise, Nutrition and Sports, Faculty of Sciences, University of Copenhagen
Copenhagen
About this study
Official title: The Role of Traditional or Western Diet in the TBC1D4 Gene on Glucose
Studies of Greenland Inuit before the 1980s found a low prevalence of type 2 diabetes (T2D) compared to Western populations. However, recent population studies in Greenland found a notably high prevalence of diabetes (9%) and pre-diabetes (19%) in the adult population.
In many studies worldwide an increase in obesity, diabetes, and cardiovascular disease has been ascribed to social transition and in particular urbanization, but the Inuit in Greenland do not fit the pattern. Paradoxically, the highest prevalence of diabetes is seen in the least urbanized areas. Thus, while previously rare, T2D has become epidemic in Inuit. In a recent study by Moltke et al found that a variant in the TBC1D4 gene was strongly associated with insulin resistance in skeletal muscle, high postprandial blood glucose and a high risk of T2D.
Read more
The rapid increase in the prevalence of T2D and other metabolic traits and the well documented genetic susceptibility indicates that lifestyle components, particularly physical activity, and diet significantly modify the genetic effects on glucose homeostasis. Thus, changing dietary habits from a diet high in traditional foods, mostly consisting of marine mammals and fish (high in protein and unsaturated fats, and low in carbohydrate) to a westernized diet, with high contents of sugar and saturated fat may have increased the T2D incidence in Arctic Inuit.
The investigators will perform a 4-week cross-over intervention study of the traditional diet versus a western diet among homozygous carriers and WTs on 2-hour glucose after an oral glucose tolerance test (OGTT). In addition, the investigators will examine the effects on cardiometabolic abnormalities such as low-grade systemic inflammation and dyslipidemia. Furthermore, the investigators will characterize the metabolic phenotype of participants, as well as gut microbiota and brown adipose tissue markers to elucidate the molecular mechanisms underlying potential improvements of a traditional Inuit diet.
Read the detailed description
The overall objective of the study is to investigate whether a traditional marine diet high in fat and low in carbohydrate compared to a westernized diet could improve glycemic control in Greenland Inuit. Furthermore, the objective is to study whether the genetic risk of postprandial hyperglycemia among Greenlandic carriers of the common nonsense p.Arg684Ter variant in the TBC1D4 gene is modified to a larger degree by the diet compared to non-carriers.
The investigators will perform a 4-week cross-over intervention study of the traditional diet versus a western diet among homozygous carriers and WTs on 2-hour glucose after an oral glucose tolerance test (OGTT). In addition, the investigators will examine the effects on cardiometabolic abnormalities such as low-grade systemic inflammation and dyslipidemia. Furthermore, the investigators will characterize the metabolic phenotype of participants, as well as gut microbiota and brown adipose tissue markers to elucidate the molecular mechanisms underlying potential improvements of a traditional Inuit diet.
The study is expected to provide relevant information in relation to whether diet has a role in preventing T2D in the large group of people who are hetero / homozygous for the TBC1D4 variant. The investigators expect this enhanced insight to be useful and valuable for future development of genotype based interventions for these persons.
For the individual participant, the results of the study are expected to provide constructive knowledge to guide the participants in which actions they could take to reduce the likelihood of developing T2D.
Hypothesis
The investigators hypothesize that the traditional marine diet very high in fat and low in carbohydrates will improve postprandial glucose handling in Greenland Inuit. Furthermore, the investigators hypothesise that this effect is modified among carriers of the common nonsense p.Arg684Ter variant in the TBC1D4 gene which will have larger effects of following the traditional marine diet.
Methodology
Overall study design 30 homozygous carriers and 30 homozygous non-carriers of the nonsense p.Arg684Ter variant in the TBC1D4 gene between 18-80 years will be included in the study.
The study will be conducted as a randomized, controlled, cross-over design, comprising two dietary intervention periods of four weeks duration, with no washout in between. The participants will be randomized to start on one of the two diet periods and cross-over to the other dietary period at 4 weeks (see figure 1). The investigators expect to recruit participants after approval from April 2019 and have the last patient last visit by September 2020. Recruitment of study participants will be based on the currently ongoing Greenland Population Study (project 2017-5582) to ensure that the investigators have 50% homozygous carriers of the nonsense p.Arg684Ter variant in the TBC1D4 gene. The study will be carried out in three geographical areas: Nuuk, Qaanaaq, and Qasigiannguit.
Randomization, allocation, concealment, and blinding
After having given oral and written consent, randomization will be performed separately for each participant based on the genotype in blocks of variable size to ensure equal randomization throughout the enrolment phase of the study. The randomization sequence will be done by an investigator without contact to the participants. The personnel conducting the study will allocate participants to the sequence of intervention using a list of participant IDs matched with allocated sequences. Blinding participants is not feasible due to the nature of the intervention, however blinding of the allocation sequence will be established during sample analysis and initial data analysis.
Intervention
Two diets will be designed for the intervention. A traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food, and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%). The Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork, and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%). Major parts (20-25E%) of the diet will be given to the participants upon start and during the study in the form of frozen goods. For the TID group, this will be marine mammals and fish, while for the Westernized group the products delivered will mainly be grains and livestock animals. Instructions for the participants regarding the incorporation of dietary changes will be performed by trained study staff.
Study products
Assessment of habitual food intake at baseline will be conducted with a previously validated food frequency questionnaire. A modified version of the food frequency questionnaire will be used at the end of each intervention period for assessing habitual diet during the intervention period. In addition, participants will be asked to keep a simple log of ingestion of delivered products to estimate compliance. The investigators will apply for sponsorship for study products. The potential study product sponsors will play no role in the design, methods, data management and analysis or in the decision to publish.
Consumption of Study products
Trained study personnel will provide participants with instructions on how to incorporate the provided study products in the diet. Initially, it will be ensured that the study products are provided in sufficient amounts to ensure ad libitum consumption. Participants will be provided individualized amounts of all study products every second week. All study products are provided as fresh or frozen products, and all food products will be picked up at the local study site.
Study examinations
Participants will arrive for clinical examination after an overnight fast of at least 8 hours. Lifestyle questionnaires, including a food frequency questionnaire and questionnaires about medication use, will be performed for baseline characterization of the participants. Blood pressure and anthropometric measurements are performed including measurements of body weight, height, waist and hip circumference, sagittal abdominal diameter and bio-impedance measurements for assessing body fat mass. A fasting blood sample is obtained and an OGTT is performed with collection of blood samples after 0, 30 and 120 min. Samples will be analyzed with standard clinical procedures for glycaemic variability markers, including glucose, insulin, c-peptide, and HbA1c, as well as plasma lipids. Circulating fatty acids profiles will be used as a marker of compliance with the TID using dried blood spots. Furthermore, fecal samples will be collected at all examination visits and kept stored for future microbiota analyses, using untargeted shotgun sequencing. Biobanked samples will be stored for further analyses which could include gastrointestinal hormones, gut microbiota metabolites, additional compliance markers such as alkylresorcinols (for grain intake) low-grade inflammation markers and markers of brown fat accumulation. In addition, participants will be equipped with a 24-h continuous glucose monitoring device for 14 days at the end of each intervention period. All 3 examination days consists of similar examinations and data collections and are estimated to last approximately 5 hours.
- Conditions
- T2D
- Being tested
- Cross-over study
- Keywords
- Greenland Inuit, Traditional diet, TBC1D4
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cross-over studyOther
Traditional Inuit Diet vs Westernized Diet
| Study group | Role | What they receive |
|---|---|---|
| Traditional Inuit Diet | Experimental | This will be a traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%). Receives: Other: Cross-over study |
| Westernized Diet | Placebo comparator | This will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%). Receives: Other: Cross-over study |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in 2-h post-OGTT glucose in blood between the baseline and endpoint change in the two periods
2 hour post oral glucose tolerance test glucose mesurement in blood (mmol/L)
Measured: Week 1, Week 4 and week 8
Secondary outcomes (17)
Changes in Hba1c between the baseline and endpoint change in the two periods
fasting measurement of blood glycated hemoglobin (%)
Measured: Week 1, Week 4 and week 8
Changes in fasting blood glucose between the baseline and endpoint change in the two periods
Fasting measurement of blood glucose (mmol/L)
Measured: Week 1, Week 4 and week 8
Changes in 30 min post OGTT between the baseline and endpoint change in the two periods
Measurement of blood glucose 30 min after OGTT (mmol/L)
Measured: Week 1, Week 4 and week 8
Continuous glucose monitoring
Continuous glucose monitor from Abbott is worn for 14 days in each period providing glucose measurements continuously (mmol/L).
Measured: Week 2 and Week 6
Insulin sensitivity and secretion
Measured as part of the OGTT. Plasma glucose (mmol/l). Plasma insulin - fasting (pmol/l)
Measured: Week 1, Week 4 and week 8
Changes in blood lipids between the baseline and endpoint change in the two periods
Measurements of total and HDL cholesterol (mmol/L) and triglycerides (mmol/L).
Measured: Week 1, Week 4 and week 8
Changes in gastrointestinal hormones between the baseline and endpoint change in the two periods
Measurements of e.g. GLP-1, PYY and GIP (pmol/L) in blood.
Measured: Week 1, Week 4 and week 8
Changes in gut microbiota composition between the baseline and endpoint change in the two periods
Measured on fecal samples
Measured: Week 1, Week 4 and week 8
Changes in C-Reactive Protein between the baseline and endpoint change in the two periods
Blood measurements of C-Reactive Protein (mg/L)
Measured: Week 1, Week 4 and week 8
Changes in Interleukin-6 between the baseline and endpoint change in the two periods
Blood measurements of Interleukin-6 (pg/mL)
Measured: Week 1, Week 4 and week 8
Changes in small metabolites between the baseline and endpoint change in the two periods
Measured using blood metabolomic measurements of amino acids, lipids, and other small metabolites (umol/L)
Measured: Week 1, Week 4 and week 8
Changes in weight between the baseline and endpoint change in the two periods
Measured using a Tanita body composition analyser. Body weight in kilograms
Measured: Week 1, Week 4 and week 8
Changes in body composition between the baseline and endpoint change in the two periods
Measured using a Tanita body composition analyser. Fat free mass and Body fat mass in kilograms used to calculate body fat percentage.
Measured: Week 1, Week 4 and week 8
Changes in waist and hip circumference between the baseline and endpoint change in the two periods
Measured using measurement tape
Measured: Week 1, Week 4 and week 8
Changes in fatty acids (compliance measurement) between the baseline and endpoint change in the two periods
Objective measures of compliance with fish intake, fatty acids (%FA) in blood.
Measured: Week 1, Week 4 and week 8
Changes in alkylresorcinols (compliance measurement) between the baseline and endpoint change in the two periods
Objective measures of compliance with grain intake, alkylresorcinols (umol/L) in blood.
Measured: Week 1, Week 4 and week 8
Changes in blood pressure (BP) between the baseline and endpoint change in the two periods
Systolic BP (mmHG) Diastolic BP (mmHG)
Measured: Week 1, Week 4 and week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2019
- Study start15 Apr 2019
- Primary completion23 Nov 2020
- Study completion23 Nov 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for T2DStudies of the same condition, open and under way.
- More trials run by University of CopenhagenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Collaborators
- Steno Diabetes Center Copenhagen, Novo Nordisk A/S
- Responsible party
- Principal investigator, Professor Lotte Lauritzen, University of Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04011904
- Sponsor's protocol ID
- KVUG 2018-26
- Status last verified
- Nov 2020
- First submitted
- 13 May 2019
- Last updated
- 25 Nov 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Moller G, Lind MV, Hauptmann AL, Senftleber N, Hansen CB, Hansen T, Jorgensen ME, Lauritzen L. The role of a traditional and western diet on glucose homeostasis in Greenlandic Inuit carriers and non-carriers of type 2 diabetes variant in the TBC1D4 gene: A protocol for a randomized clinical trial. Contemp Clin Trials Commun. 2021 Jan 27;21:100734. doi: 10.1016/j.conctc.2021.100734. eCollection 2021 Mar.
PubMed 33604488
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Traditional or Western Diet in the TBC1D4 Gene on Glucose
- ClinicalTrials.gov ID
- NCT04011904
- Acronym / sponsor ID
- KVUG 2018-26
- Conditions
- T2D
- Keywords
- Greenland Inuit, Traditional diet, TBC1D4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Collaborators
- Steno Diabetes Center Copenhagen, Novo Nordisk A/S
- Study start
- 15 Apr 2019 (actual)
- Primary completion
- 23 Nov 2020 (actual)
- Study completion
- 23 Nov 2020 (actual)
- First posted
- 9 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Studies of Greenland Inuit before the 1980s found a low prevalence of type 2 diabetes (T2D) compared to Western populations. However, recent population studies in Greenland found a notably high prevalence of diabetes (9%) and pre-diabetes (19%) in the adult population.
In many studies worldwide an increase in obesity, diabetes, and cardiovascular disease has been ascribed to social transition and in particular urbanization, but the Inuit in Greenland do not fit the pattern. Paradoxically, the highest prevalence of diabetes is seen in the least urbanized areas. Thus, while previously rare, T2D has become epidemic in Inuit. In a recent study by Moltke et al found that a variant in the TBC1D4 gene was strongly associated with insulin resistance in skeletal muscle, high postprandial blood glucose and a high risk of T2D.
The rapid increase in the prevalence of T2D and other metabolic traits and the well documented genetic susceptibility indicates that lifestyle components, particularly physical activity, and diet significantly modify the genetic effects on glucose homeostasis. Thus, changing dietary habits from a diet high in traditional foods, mostly consisting of marine mammals and fish (high in protein and unsaturated fats, and low in carbohydrate) to a westernized diet, with high contents of sugar and saturated fat may have increased the T2D incidence in Arctic Inuit.
The investigators will perform a 4-week cross-over intervention study of the traditional diet versus a western diet among homozygous carriers and WTs on 2-hour glucose after an oral glucose tolerance test (OGTT). In addition, the investigators will examine the effects on cardiometabolic abnormalities such as low-grade systemic inflammation and dyslipidemia. Furthermore, the investigators will characterize the metabolic phenotype of participants, as well as gut microbiota and brown adipose tissue markers to elucidate the molecular mechanisms underlying potential improvements of a traditional Inuit diet.
Detailed description
The overall objective of the study is to investigate whether a traditional marine diet high in fat and low in carbohydrate compared to a westernized diet could improve glycemic control in Greenland Inuit. Furthermore, the objective is to study whether the genetic risk of postprandial hyperglycemia among Greenlandic carriers of the common nonsense p.Arg684Ter variant in the TBC1D4 gene is modified to a larger degree by the diet compared to non-carriers.
The investigators will perform a 4-week cross-over intervention study of the traditional diet versus a western diet among homozygous carriers and WTs on 2-hour glucose after an oral glucose tolerance test (OGTT). In addition, the investigators will examine the effects on cardiometabolic abnormalities such as low-grade systemic inflammation and dyslipidemia. Furthermore, the investigators will characterize the metabolic phenotype of participants, as well as gut microbiota and brown adipose tissue markers to elucidate the molecular mechanisms underlying potential improvements of a traditional Inuit diet.
The study is expected to provide relevant information in relation to whether diet has a role in preventing T2D in the large group of people who are hetero / homozygous for the TBC1D4 variant. The investigators expect this enhanced insight to be useful and valuable for future development of genotype based interventions for these persons.
For the individual participant, the results of the study are expected to provide constructive knowledge to guide the participants in which actions they could take to reduce the likelihood of developing T2D.
Hypothesis
The investigators hypothesize that the traditional marine diet very high in fat and low in carbohydrates will improve postprandial glucose handling in Greenland Inuit. Furthermore, the investigators hypothesise that this effect is modified among carriers of the common nonsense p.Arg684Ter variant in the TBC1D4 gene which will have larger effects of following the traditional marine diet.
Methodology
Overall study design 30 homozygous carriers and 30 homozygous non-carriers of the nonsense p.Arg684Ter variant in the TBC1D4 gene between 18-80 years will be included in the study.
The study will be conducted as a randomized, controlled, cross-over design, comprising two dietary intervention periods of four weeks duration, with no washout in between. The participants will be randomized to start on one of the two diet periods and cross-over to the other dietary period at 4 weeks (see figure 1). The investigators expect to recruit participants after approval from April 2019 and have the last patient last visit by September 2020. Recruitment of study participants will be based on the currently ongoing Greenland Population Study (project 2017-5582) to ensure that the investigators have 50% homozygous carriers of the nonsense p.Arg684Ter variant in the TBC1D4 gene. The study will be carried out in three geographical areas: Nuuk, Qaanaaq, and Qasigiannguit.
Randomization, allocation, concealment, and blinding
After having given oral and written consent, randomization will be performed separately for each participant based on the genotype in blocks of variable size to ensure equal randomization throughout the enrolment phase of the study. The randomization sequence will be done by an investigator without contact to the participants. The personnel conducting the study will allocate participants to the sequence of intervention using a list of participant IDs matched with allocated sequences. Blinding participants is not feasible due to the nature of the intervention, however blinding of the allocation sequence will be established during sample analysis and initial data analysis.
Intervention
Two diets will be designed for the intervention. A traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food, and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%). The Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork, and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%). Major parts (20-25E%) of the diet will be given to the participants upon start and during the study in the form of frozen goods. For the TID group, this will be marine mammals and fish, while for the Westernized group the products delivered will mainly be grains and livestock animals. Instructions for the participants regarding the incorporation of dietary changes will be performed by trained study staff.
Study products
Assessment of habitual food intake at baseline will be conducted with a previously validated food frequency questionnaire. A modified version of the food frequency questionnaire will be used at the end of each intervention period for assessing habitual diet during the intervention period. In addition, participants will be asked to keep a simple log of ingestion of delivered products to estimate compliance. The investigators will apply for sponsorship for study products. The potential study product sponsors will play no role in the design, methods, data management and analysis or in the decision to publish.
Consumption of Study products
Trained study personnel will provide participants with instructions on how to incorporate the provided study products in the diet. Initially, it will be ensured that the study products are provided in sufficient amounts to ensure ad libitum consumption. Participants will be provided individualized amounts of all study products every second week. All study products are provided as fresh or frozen products, and all food products will be picked up at the local study site.
Study examinations
Participants will arrive for clinical examination after an overnight fast of at least 8 hours. Lifestyle questionnaires, including a food frequency questionnaire and questionnaires about medication use, will be performed for baseline characterization of the participants. Blood pressure and anthropometric measurements are performed including measurements of body weight, height, waist and hip circumference, sagittal abdominal diameter and bio-impedance measurements for assessing body fat mass. A fasting blood sample is obtained and an OGTT is performed with collection of blood samples after 0, 30 and 120 min. Samples will be analyzed with standard clinical procedures for glycaemic variability markers, including glucose, insulin, c-peptide, and HbA1c, as well as plasma lipids. Circulating fatty acids profiles will be used as a marker of compliance with the TID using dried blood spots. Furthermore, fecal samples will be collected at all examination visits and kept stored for future microbiota analyses, using untargeted shotgun sequencing. Biobanked samples will be stored for further analyses which could include gastrointestinal hormones, gut microbiota metabolites, additional compliance markers such as alkylresorcinols (for grain intake) low-grade inflammation markers and markers of brown fat accumulation. In addition, participants will be equipped with a 24-h continuous glucose monitoring device for 14 days at the end of each intervention period. All 3 examination days consists of similar examinations and data collections and are estimated to last approximately 5 hours.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Traditional Inuit Diet | Experimental | Other: Cross-over studyThis will be a traditional Inuit diet (TID) rich in marine mammals (such as walrus, seal, and whale), fish, caribou and musk ox, with low intake of grains, fast food and other imported foods. The TID diet will be high in fat (>40 of the energy (E%)) and low in carbohydrate (<30 E%). |
| Westernized Diet | Placebo comparator | Other: Cross-over studyThis will be a Westernized diet will be consisting of high amounts of grains, potatoes, rice and imported meats from livestock animals (beef, pork and chicken). The Westernized diet will be high in carbohydrate (55-65 E%) and lower in fat (30-35 E%). |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Participants who have provided written informed consent
- Age between 18 and 80 years
- Homozygous carriers of the nonsense p.Arg684Ter variant in the TBC1D4 gene (cases)
- Homozygous non-carriers of the nonsense p.Arg684Ter variant in the TBC1D4 gene (control)
Key exclusion criteria (5 listed)
- If study participants do not want to know whether they are carriers or non-carriers of the p.Arg684Ter variant in the TBC1D4 gene they will not be able to participate in the study
- BMI ≥ 18.5 kg/m2
- Diagnosis of diabetes (HbA1c ≥ 6,5% (48 mmol/mol)) or pharmacological treatment of diabetes (10).
- Use of peroral glucocorticoids
- Lack of compliance with the procedures in the study protocol, judged by Investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cross-over studyTraditional Inuit Diet vs Westernized Diet | Other | Traditional Inuit Diet, Westernized Diet |
Primary outcome
Changes in 2-h post-OGTT glucose in blood between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
2 hour post oral glucose tolerance test glucose mesurement in blood (mmol/L)
17 secondary outcomes
Changes in Hba1c between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in fasting blood glucose between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in 30 min post OGTT between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Continuous glucose monitoring
Time frame: Week 2 and Week 6
Insulin sensitivity and secretion
Time frame: Week 1, Week 4 and week 8
Changes in blood lipids between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in gastrointestinal hormones between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in gut microbiota composition between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in C-Reactive Protein between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in Interleukin-6 between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in small metabolites between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in weight between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in body composition between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in waist and hip circumference between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in fatty acids (compliance measurement) between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in alkylresorcinols (compliance measurement) between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Changes in blood pressure (BP) between the baseline and endpoint change in the two periods
Time frame: Week 1, Week 4 and week 8
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2020.
- Derived from this study: PubMed 33604488Moller G, Lind MV, Hauptmann AL, Senftleber N, Hansen CB, Hansen T, Jorgensen ME, Lauritzen L. The role of a traditional and western diet on glucose homeostasis in Greenlandic Inuit carriers and non-carriers of type 2 diabetes variant in the TBC1D4 gene: A protocol for a randomized clinical trial. Contemp Clin Trials Commun. 2021 Jan 27;21:100734. doi: 10.1016/j.conctc.2021.100734. eCollection 2021 Mar.
- Individual participant dataSharing planned: No
Related trials for T2D
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cross-over study in people with T2D, run by University of Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in 2-h post-OGTT glucose in blood between the baseline and endpoint change in the two periods (time frame: Week 1, Week 4 and week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04011904, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2020.